Clinical trials
Advanced Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting advanced pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 135 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT07155850Recruiting
Testing YntraDose before chemotherapy for advanced pancreas cancer
This trial tests a new treatment called YntraDose, given directly into the pancreas tumor before standard chemotherapy. It is for people with locally advanced pancreatic cancer that cannot be removed by surgery.
RomaAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Tucson, ArizonaAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT04146298RecruitingPhase 1/Phase 2
KRAS-mutant pancreatic cancer T-cell therapy for some people
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
ShanghaiAges 18–75 - NCT04406831Recruiting
Testing microRNA for pancreatic cancer diagnosis and treatment response
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Norwalk, ConnecticutAges 18 years+ - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05132244Recruiting
Checking and treating blood sugar in pancreatic cancer
This trial tests a plan to monitor and manage blood sugar in people with pancreatic ductal cancer who are starting a specific chemotherapy regimen (FOLFIRINOX). The goal is to prevent or address high blood sugar during treatment, which may help people stay on therapy safely.
Vancouver, British ColumbiaAges 18 years+ - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05475366Recruiting
Choosing the right first chemotherapy for advanced pancreatic cancer
This trial tests a personalized approach to selecting your first chemotherapy based on tumor gene activity. It aims to match treatment to your cancer’s biology to improve outcomes for people with advanced (metastatic) pancreatic cancer.
ClichyAges 18–75 - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05723107RecruitingPhase 1
Testing an endoscopic treatment for pancreatic cancer that can't be removed
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
New York, New YorkAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+
Hear when a new Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 135 recruiting advanced pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.